These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35662610)

  • 21. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
    Dhaliwal A; Zheng G
    Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
    Natfji AA; Ravishankar D; Osborn HMI; Greco F
    J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Navigations of the targeting pathway of nanomedicines toward tumor.
    Tao Y; Lan X; Zhang Y; Qing G; Wang J; Xiao Y; Chen H; Liu L; Liang XJ; Guo W
    Expert Opin Drug Deliv; 2022 Aug; 19(8):985-996. PubMed ID: 35929954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
    Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour extravasation of nanomedicine: The EPR and alternative pathways.
    Shen Y; Bae YH
    Adv Drug Deliv Rev; 2023 Mar; 194():114707. PubMed ID: 36657644
    [No Abstract]   [Full Text] [Related]  

  • 26. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
    Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies of engineering nanomedicines for tumor retention.
    Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
    J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery.
    Zhang B; Hu Y; Pang Z
    Front Pharmacol; 2017; 8():952. PubMed ID: 29311946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advocation and advancements of EPR effect theory in drug delivery science: A commentary.
    Hashida M
    J Control Release; 2022 Jun; 346():355-357. PubMed ID: 35483640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: latest trends, obstacles and future perspective.
    Shekhar S; Chauhan M; Sonali ; Yadav B; Dutt R; Hu L; Muthu MS; Singh RP
    Nanomedicine (Lond); 2022 Aug; 17(18):1213-1216. PubMed ID: 36136592
    [No Abstract]   [Full Text] [Related]  

  • 34. Polysaccharide-based nanocarriers for efficient transvascular drug delivery.
    Zhang M; Ma H; Wang X; Yu B; Cong H; Shen Y
    J Control Release; 2023 Feb; 354():167-187. PubMed ID: 36581260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
    Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
    Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
    Dawidczyk CM; Kim C; Park JH; Russell LM; Lee KH; Pomper MG; Searson PC
    J Control Release; 2014 Aug; 187():133-44. PubMed ID: 24874289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leukocytes as carriers for targeted cancer drug delivery.
    Mitchell MJ; King MR
    Expert Opin Drug Deliv; 2015 Mar; 12(3):375-92. PubMed ID: 25270379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
    Maeda H
    Cancer Sci; 2013 Jul; 104(7):779-89. PubMed ID: 23495730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.